OBJECTIVE: To determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. METHODS: We examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross-sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI. RESULTS: In linear regression analyses adjusted for age, sex, education, body mass index, APOE ε4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median = 3.7-year follow-up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR) = 2.75; 95% CI = 1.64, 4.63, P < .001). Similarly, other oral medications (SHR = 1.96; 95% CI = 1.19, 3.25; P = .009) and insulin (SHR = 3.17; 95% CI = 1.27, 7.92; P = .014) use were also associated with risk of MCI diagnosis. CONCLUSIONS: These findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.
OBJECTIVE: To determine the cross-sectional and longitudinal associations between diabetes treatment type and cognitive outcomes among type II diabetics. METHODS: We examined the association between metformin use, as compared to other diabetic treatment (ie, insulin, other oral medications, and diet/exercise) and cognitive test performance and mild cognitive impairment (MCI) diagnosis among 508 cognitively unimpaired at baseline type II diabetics enrolled in the Mayo Clinic Study of Aging. We created propensity scores to adjust for treatment effects. We used multivariate linear and logistic regression models to investigate the cross-sectional association between treatment type and cognitive test z scores, respectively. Mixed effects models and competing risk regression models were used to determine the longitudinal association between treatment type and change in cognitive test z scores and risk of developing incident MCI. RESULTS: In linear regression analyses adjusted for age, sex, education, body mass index, APOE ε4, insulin treatment, medical comorbidities, number of medications, duration of diabetes, and propensity score, we did not observe an association between metformin use and cognitive test performance. Additionally, we did not observe an association between metformin use and cognitive test performance over time (median = 3.7-year follow-up). Metformin was associated with an increased risk of MCI (subhazard ratio (SHR) = 2.75; 95% CI = 1.64, 4.63, P < .001). Similarly, other oral medications (SHR = 1.96; 95% CI = 1.19, 3.25; P = .009) and insulin (SHR = 3.17; 95% CI = 1.27, 7.92; P = .014) use were also associated with risk of MCI diagnosis. CONCLUSIONS: These findings suggest that metformin use, as compared to management of diabetes with other treatments, is not associated with cognitive test performance. However, metformin was associated with incident MCI diagnosis.
Authors: Joanne S Allard; Evelyn J Perez; Koji Fukui; Priscilla Carpenter; Donald K Ingram; Rafael de Cabo Journal: Behav Brain Res Date: 2015-12-14 Impact factor: 3.332
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca Journal: Int J Epidemiol Date: 2012-11-18 Impact factor: 7.196
Authors: Alexandra M V Wennberg; Deborah Gustafson; Clinton E Hagen; Rosebud O Roberts; David Knopman; Clifford Jack; Ronald C Petersen; Michelle M Mielke Journal: J Alzheimers Dis Date: 2016-05-04 Impact factor: 4.472
Authors: Amir Qaseem; Michael J Barry; Linda L Humphrey; Mary Ann Forciea; Nick Fitterman; Carrie Horwitch; Devan Kansagara; Robert M McLean; Timothy J Wilt Journal: Ann Intern Med Date: 2017-01-03 Impact factor: 25.391
Authors: Rosebud O Roberts; David S Knopman; Yonas E Geda; Ruth H Cha; V Shane Pankratz; Luke Baertlein; Bradley F Boeve; Eric G Tangalos; Robert J Ivnik; Michelle M Mielke; Ronald C Petersen Journal: Alzheimers Dement Date: 2013-04-03 Impact factor: 21.566
Authors: Gregory N Ruegsegger; Patrick M Vanderboom; Surendra Dasari; Katherine A Klaus; Parijat Kabiraj; Christina B McCarthy; Claudia F Lucchinetti; K Sreekumaran Nair Journal: JCI Insight Date: 2019-09-19
Authors: Sheri J Hartman; Sandahl H Nelson; Catherine R Marinac; Loki Natarajan; Barbara A Parker; Ruth E Patterson Journal: Psychooncology Date: 2019-06-27 Impact factor: 3.894
Authors: Kamonthip Tanglakmankhong; Benjamin M Hampstead; Robert J Ploutz-Snyder; Kathleen Potempa Journal: Pac Rim Int J Nurs Res Thail Date: 2020-12-08
Authors: Che-Yuan Wu; Michael Ouk; Yuen Yan Wong; Natasha Z Anita; Jodi D Edwards; Pearl Yang; Baiju R Shah; Nathan Herrmann; Krista L Lanctôt; Moira K Kapral; Bradley J MacIntosh; Jennifer S Rabin; Sandra E Black; Walter Swardfager Journal: Alzheimers Dement Date: 2020-08-16 Impact factor: 16.655